Background: We aim to analyze patients undergoing re-transplantation for HAT in the US.

Methods:Between 1995 and 2015, 623 patients were re-transplanted for HAT identified in the UNOS dataset.

Results: The mean age in the HAT group was 51.25+10.4 years, mean BMI was 26.72 kg/m², and mean MELD score was 19.62+9.09. HAT recipients were more likely to be male, older, with higher rates of pre-transplant portal vein thrombosis (7.4 vs. 5.4%, p=0.04), lower incidence of hepatitis C (29.5% vs. 35.8%, p=0.002), shorter length of hospitalization (23 vs. 26 days, p=0.02), shorter waiting time for transplant (61 vs. 111 days, p=0.001), and had lower 90 day mortality (16% vs. 20%, p=0.02). Patients re-transplanted for HAT had 13% decrease risk of graft loss and 13% increased long term survival. After case-control matched analysis graft and patient survival was significantly better in the HAT group. Late re-transplantation for HAT was associated with a decreased graft and patient survival compared to those re-re-transplanted early (within 30days).

Conclusions: Selected patients undergoing re-transplantation for HAT have better outcomes compared to those re-transplanted for other indications. Early re-transplantation is associated with better outcomes and should be considered in those with HAT.

CITATION INFORMATION: Garcia C., Mei X., Marti F., Shah M., Berger J., Daily M., Gupta M., Gedaly R. Re-Transplantation for Hepatic Artery Thrombosis: A National Perspective Am J Transplant. 2017;17 (suppl 3).

« Back to 2018 American Transplant Congress